Skip to main content
. 2019 May 17;37(19):1608–1616. doi: 10.1200/JCO.19.00538

FIG 3.

FIG 3.

Progression-free survival per investigator. NIVO3, nivolumab 3 mg/kg monotherapy every 2 weeks; NIVO3+IPI1, nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; NIVO1+IPI3, nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; PFS, progression-free survival.